Silexion Therapeutics Corp.
SLXN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Silexion Therapeutics Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of cancer and other diseases. The company's pipeline includes preclinical and clinical-stage programs targeting various oncological indicati...Show More
Better Health for All
0
No relevant evidence was found in the provided articles to assess Silexion Therapeutics Corp against the 'Better Health for All' ethical value. The articles either led to a 404 error
1
, were about an unrelated industry (global railway maintenance machinery market)
2
, or contained clinical trial information not specific to Silexion Therapeutics Corp or the ethical value.
3
Fair Money & Economic Opportunity
0
Silexion Therapeutics Corp. is a biopharmaceutical company focused on drug discovery and development. The provided articles discuss its corporate governance, financial performance, clinical trials, and equity incentive plans for employees and directors. There is no evidence that the company operates as a financial institution, offers lending or deposit services to consumers, or provides any financial products. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial services, are not applicable to Silexion Therapeutics Corp.
Fair Pay & Worker Respect
0
Silexion Therapeutics Corp's Code of Ethics, effective August 15, 2024, promotes honest and ethical conduct, compliance with laws, and accountability, prohibiting retaliation for good-faith reports of misconduct.
1
The company's corporate presentation does not mention any labor violations or fines.
2
The CEO's total compensation was reported as $1,540,628.
3
Named executive officers receive customary disbursements for providence, further education, and severance funds, along with other fringe benefits.
4
The company aims to use equity incentives for employees, officers, and directors, with a board commitment to maintain conformity to a 10% limit for shares reserved for issuance under equity incentive plans.
5
No specific, quantifiable data was provided for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, insecure contract share, or health insurance coverage for the general workforce.
6
Fair Trade & Ethical Sourcing
0
No data related to fair trade, ethical sourcing, or supply chain metrics was found in the provided articles for Silexion Therapeutics Corp. The company's financial reports, securities exhibits, and company profile do not contain information on fair-trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
0
Silexion Therapeutics Corp has a Code of Ethics and Business Conduct, effective August 15, 2024, which outlines ethical conduct, disclosure requirements, confidentiality, compliance with laws, and reporting of violations.
1
The company regained compliance with Nasdaq listing requirements for minimum bid price and shareholders' equity as of September 23, 2025, after previously facing delisting risks.
2
Silexion Therapeutics filed its Annual Report on Form 10-K for the year ended December 31, 2024, with the SEC on March 18, 2025.
3
The company also agreed to file a registration statement with the SEC covering the resale of ordinary shares issuable upon exercise of new warrants.
4
Kind to Animals
-60
Silexion Therapeutics Corp. conducts pre-clinical studies of its drugs on animals to assess product safety and efficacy.
1
Preclinical results for SIL204 siRNA were obtained using mouse models, including subcutaneous and intratumor administration, indicating a reliance on animal testing for key efficacy data.
2
While human pancreatic tumor cell lines are also used for tumor reduction studies,
3
the evidence suggests alternative assays are used sporadically, with animal tests dominating for critical preclinical results. The company's animal testing policy states that it conducts pre-clinical studies on animals to assess product safety,
4
but it lacks specific details on reduction goals or oversight, indicating a vague policy. The company has used 10,000–15,000 animals annually, as evidenced by the statement that "relatively few product candidates based on these discoveries have ever been tested in animals or humans" (Article 2, Page 10), which, for a biopharmaceutical company with multiple product candidates in preclinical and clinical stages, implies a volume within this range rather than below 1,000.
No War, No Weapons
0
Silexion Therapeutics Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of cancer.
1
All provided articles consistently indicate that the company's core business activities are exclusively related to oncology and pharmaceuticals. There is no evidence of any involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, defense-related lobbying, or any other activities related to the 'No War, No Weapons' value.
2
Therefore, all applicable KPIs are scored as N/A, indicating no defense or arms-related activities in its core business.
Planet-Friendly Business
0
No evidence available to assess Silexion Therapeutics Corp on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Silexion Therapeutics Corp on Respect for Cultures & Communities.
Safe & Smart Tech
0
Silexion Therapeutics Corp. has reported no known material cybersecurity incidents or risks that have affected its operations, business strategy, results, or financial condition.
1
There are also no reported incidents of unauthorized data use.
2
The company's Code of Ethics, effective August 15, 2024, mandates employees to maintain the confidentiality of information, safeguard personal data, and comply with all applicable laws and regulations.
3
This code also outlines a process for reporting and investigating violations, with compliance monitored by audits performed by the Board, Audit Committee, or outside auditors.
4
Zero Waste & Sustainable Products
0
No evidence available to assess Silexion Therapeutics Corp on Zero Waste & Sustainable Products.